Abstract 5139
Background
The prognostic value of the inflammatory indexes (eg. neutrophil-to-lymphocyte ratio, NLR; and systemic immune-inflammation index, SII) was demonstrated among patients with epithelial ovarian cancer (EOC). This study aimed to evaluate their predictive value in terms of platinum-free interval (PFI) as regard to bevacizumab treatment received.
Methods
A total of 375 EOC patients were retrospectively analyzed, 301 treated with chemotherapy alone and 74 with bevacizumab, with the decision to include this drug in the chemotherapy regimen left to the discretion of the treating physician. The correlation between NLR (defined as the ratio of neutrophil to lymphocyte count) and SII, calculated as (platelet count × neutrophil count)/lymphocyte count, and PFI were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Cutoff values were determined using Receiver Operating Characteristic (ROC) analysis.
Results
In univariate analysis, patients with high NLR (≥3) and SII (≥730) had a significantly shorter PFI at 6 and 12 months in overall cohort. In multivariate analysis, only NLR was an independent predictive factor for PFI at 6 months (OR = 2.52, 95% CI 1.30–4.87, p = 0.006) and at 12 months (OR = 2.05, 95% CI 1.05–4.01, p = 0.036) in the overall population and in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004; HR = 2.27, 95% CI 1.10–4.70, p = 0.027, respectively). Inflammatory indexes were not predictive for PFI in the bevacizumab group (Table).Table: 1020P
PFI at 6 months | PFI at 12 months | |||||||
---|---|---|---|---|---|---|---|---|
N. pts | N. pts | OR (95% CI) | p | N. pts | N. pts | OR (95% CI) | p | |
NLR | ||||||||
<3 | 74 | 139 | 1.00 | 113 | 98 | 1.00 | ||
≥3 | 80 | 68 | 2.52 (1.30-4.87) | 0.006 | 106 | 37 | 2.05 (1.05-4.01) | 0.036 |
SII | ||||||||
<730 | 52 | 99 | 1.00 | 76 | 73 | 1.00 | ||
≥730 | 102 | 108 | 0.74 (0.36-1.53) | 0.413 | 143 | 62 | 0.91 (0.45-1.84) | 0.786 |
CT | ||||||||
NLR | ||||||||
<3 | 62 | 115 | 1.00 | 98 | 78 | 1.00 | ||
≥3 | 69 | 48 | 2.77 (1.38-5.56) | 0.004 | 89 | 24 | 2.27 (1.10-4.70) | 0.027 |
SII | ||||||||
<730 | 41 | 80 | 1.00 | 63 | 56 | 1.00 | ||
≥730 | 90 | 83 | 0.76 (0.35-1.67) | 0.498 | 124 | 46 | 0.84 (0.39-1.82) | 0.663 |
CT+B | ||||||||
NLR | ||||||||
<3 | 12 | 24 | 1.00 | 15 | 20 | 1.00 | ||
≥3 | 11 | 20 | 0.47 (0.04-5.15) | 0.538 | 17 | 13 | 0.75 (0.11-5.25) | 0.774 |
SII | ||||||||
<730 | 11 | 19 | 1.00 | 13 | 17 | 1.00 | ||
≥730 | 12 | 25 | 1.65 (0.13-20.56) | 0.696 | 19 | 16 | 1.78 (0.21-15.14) | 0.599 |
Conclusions
The NLR was an independent predictive factor for platinum-sensitivity in patients with EOC treated with chemotherapy. Its predictive role seems to be lost in patients treated with bevacizumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MITO group.
Funding
MITO group.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract